Review article · 2019 · Open access

Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis

Yuya Mizuno, Robert Ali McCutcheon, Stefan Peter Brugger, Oliver David Howes

Neuropsychopharmacology, 45(4), 622–631 · Published 25 November 2019 · DOI 10.1038/s41386-019-0577-3

Open PDFView at the publisherCite this paper

In brief

“Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis” is a 2019 review article by Yuya Mizuno and 3 co-authors, published in Neuropsychopharmacology. OpenAlex counts 125 citations as of 20 November 2026, which puts it in the top 1% of works published in 2019 by citations. It is open access under a CC BY licence: the full text is free to read at Neuropsychopharmacology.

Citations
125
Most cited in
2023 (22)
Field-weighted impact
1.46
References
85
Authors
4

Abstract

Two important clinical questions are whether there is a subtype of schizophrenia which responds differently to clozapine relative to other antipsychotics, and whether greater efficacy of clozapine is dependent on the degree of treatment-resistance. The authors address this by examining both variability and magnitude of response in patients treated with clozapine and other antipsychotics for both treatment-resistant schizophrenia (TRS) and non-resistant schizophrenia. Double-blind randomised controlled trials comparing clozapine with other antipsychotics in patients with schizophrenia were identified using five databases. Standard deviations and means of change in total, positive, and negative symptoms were extracted. Variability ratio (VR) and coefficient of variation ratio (CVR) were used to quantify relative variability in symptom change. Hedges' g was used to quantify mean differences. Ten TRS studies (n = 822) and 29 non-TRS studies (n = 2566) were meta-analysed. Relative variability in change of total symptoms did not differ significantly between clozapine and other antipsychotics in TRS studies (VR = 1.84; 95%CI, 0.85-4.02). These findings were similar with CVR, and for positive and negative symptoms. Clozapine was superior to other antipsychotics in improving total symptoms in both TRS (g = 0.34; 95%CI, 0.13-0.56) and non-TRS (g = 0.20; 95%CI, 0.08-0.32) studies. Furthermore, clozapine was superior in improving positive symptoms in both study groups, but not for negative symptoms. Pooled effect sizes showed no significant difference between TRS and non-TRS studies. These findings do not support a subtype of schizophrenia which responds specifically to clozapine. Clozapine is more effective than other antipsychotics irrespective of treatment-resistance, arguing for its use more generally in schizophrenia. PROSPERO CRD42018086507.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Mizuno, Y., McCutcheon, R. A., Brugger, S. P., & Howes, O. D. (2019). Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis. Neuropsychopharmacology, 45(4), 622–631. https://doi.org/10.1038/s41386-019-0577-3

MLA 9

Mizuno, Yuya, et al. “Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis.” Neuropsychopharmacology, vol. 45, no. 4, 2019, pp. 622–631. https://doi.org/10.1038/s41386-019-0577-3.

Chicago

Mizuno, Yuya, Robert Ali McCutcheon, Stefan Peter Brugger, and Oliver David Howes. 2019. “Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis.” Neuropsychopharmacology 45 (4): 622–631. https://doi.org/10.1038/s41386-019-0577-3.

Harvard

Mizuno, Y. et al. (2019) ‘Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis’, Neuropsychopharmacology, 45(4), pp. 622–631. doi:10.1038/s41386-019-0577-3.

IEEE

Y. Mizuno, R. A. McCutcheon, S. P. Brugger, and O. D. Howes, “Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis,” Neuropsychopharmacology, vol. 45, no. 4, pp. 622–631, 2019, doi: 10.1038/s41386-019-0577-3.

BibTeX

@article{mizuno2019heterogeneity,
  title     = {{Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis}},
  author    = {Mizuno, Yuya and McCutcheon, Robert Ali and Brugger, Stefan Peter and Howes, Oliver David},
  journal   = {Neuropsychopharmacology},
  year      = {2019},
  volume    = {45},
  number    = {4},
  pages     = {622--631},
  doi       = {10.1038/s41386-019-0577-3},
  url       = {https://doi.org/10.1038/s41386-019-0577-3}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20201111
20211717
20221616
20232222
20241919
20252222
20261818

Its field-weighted citation impact is 1.46: it has been cited 1.46 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • schizophrenia
  • treatment-resistant schizophrenia
  • clozapine
  • antipsychotic efficacy
  • treatment response heterogeneity
  • symptom variability
  • positive symptoms
  • negative symptoms

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Mizuno, Y., McCutcheon, R. A., Brugger, S. P., & Howes, O. D. (2019). Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis. Neuropsychopharmacology, 45(4), 622–631. https://doi.org/10.1038/s41386-019-0577-3

How many times has this paper been cited?

125 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Neuropsychopharmacology: sign in and open the PDF from this page.

Who wrote this paper?

Yuya Mizuno, Robert Ali McCutcheon, Stefan Peter Brugger, Oliver David Howes.

What is the DOI of this paper?

10.1038/s41386-019-0577-3, permanently at https://doi.org/10.1038/s41386-019-0577-3. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.